A BRET biosensor for measuring uncompetitive engagement of PRMT5 complexes in cells - Nature Communications This study presents a BRET biosensor that measures how anticancer drugs cooperatively engage PRMT5 complexes in cells, revealing how cellular metabolites such as SAM and MTA enhance drug action and en...

New in @natcomms.nature.com: a live-cell BRET biosensor to study how PRMT5 inhibitors engage their target in a tumour-context cellular environment (1/4)

Open access paper: doi.org/10.1038/s414...

A non-enzymatic role of Nudix hydrolase 5 in repressing purine de novo synthesis Folate metabolism is intricately linked to purine de novo synthesis through the incorporation of folate-derived one-carbon units into the purine scaffold. By investigating chemical and genetic depende...

New in @science.org 🧬

What if an enzyme you thought you knew turned out to control metabolism in a completely new way?

We found that NUDT5 acts as a molecular handbrake on purine synthesis, reshaping how cells make DNA building blocks and respond to cancer drugs.

www.science.org/doi/10.1126/...

GreenMan Festical 2025 - CMD stall

Researchers from the Centre for Medicines Discovery delivered a successful public engagement event at the 2025 Green Man Festival. Their 'Medicine-Making Express' stall demystified the drug discovery journey for a national audience, engaging over 900 visitors.
www.cmd.ox.ac.uk/news/cmd-dri...

🚀 On July 21, the Chemical Probes Portal celebrates 10 years! Launched after the landmark 2015 @NatChemBio paper by Arrowsmith et al., it now features >1150 compounds, >600 targets, and 1600+ expert reviews—powering better biomedical research. 🧪🔬
👉 chemicalprobes.org #ChemicalBiology @icr.ac.uk

Cryo-EM studies by the Bullock group @cmd.ox.ac.uk reveal how phase II drug UM171 and cancer mutations similarly reshape E3 ligase KBTBD4 to recruit neosubstrate HDAC1/2. This unexpected structural mimicry may inspire future degrader discovery. #TPD #CancerBiology rdcu.be/egdFy

AI-Powered Databases Boost the Alzheimer’s Drug Discovery Process Researchers studying Alzheimer’s disease are using artificial intelligence-powered databases to accelerate the drug discovery process by making it easier to sift through vast amounts of biomedical dat...

The ODDI has been featured in a Wall Street Journal article, describing the use of AI in identifying and stratifying novel targets for therapeutic intervention in Alzheimer’s disease.

www.wsj.com/articles/ai-...

Prof Daniel Ebner and Georgie Maynard in the lab

Georgie Maynard and brother Charlie - LibDem MP for Witney, visited the Centre for Medicines Discovery, University of Oxford Brain Tumour Charity/CRUK funded research team led by Prof Daniel Ebner working on a five-year study to identify existing cancer drugs could shrink glioblastoma brain tumours.